We treated 14 patients who had an initial serum theophylline concentration greater than 30 pglml(48.3 f 19.4 kglrnl) and symptoms of theophylline toxicity with oral activated charcoal (OAC). Thirty-gram doses of OAC were administered approximately every two hours for two to four doses. Ten patients tolerated OAC and demonstrated a reduction in theophylline half-life to 5.6 f 2.5 hours with resolution of symptoms. Three of these ten patients were treated in the emergency department and discharged, making hospitali-T heophylline preparations are among the most commonly prescribed medications for the treatment of bronchospasm. However, the therapeutic index is narrow, the metabolism of the drug varies widely among individuals,' and there are a number of disorders, medications, and other factors which may impair theophylline clearance leading to toxic serum level^.^ The therapeutic range of serum theophylline concentration is 10 to 20 kglml. Virtually all patients with serum levels greater than 30 kg/ml have some manifestations of theophylline to~icity,"~ most commonly tachycardia, nausea, and anxiety. Severe theophylline intoxication may be complicated by tachyarrhythmias, seizures, shock, and death.'.'
T
heophylline preparations are among the most commonly prescribed medications for the treatment of bronchospasm. However, the therapeutic index is narrow, the metabolism of the drug varies widely among individuals,' and there are a number of disorders, medications, and other factors which may impair theophylline clearance leading to toxic serum level^.^ The therapeutic range of serum theophylline concentration is 10 to 20 kglml. Virtually all patients with serum levels greater than 30 kg/ml have some manifestations of theophylline to~icity,"~ most commonly tachycardia, nausea, and anxiety. Severe theophylline intoxication may be complicated by tachyarrhythmias, seizures, shock, and death.'. ' Treatment of theophylline intoxication includes withdrawal of the offending agent, management of complications, oral administration of activated charcoal, and in severe cases, charcoal he moper fusion."^'
Inhibition of absorption of oral theophylline8 and enhanced clearance of intravenously adminstered theophyl1ine"'O has been demonstrated in normal volunteers treated with oral activated charcoal (OAC). However, reports describing the clinical use of OAC for theophylline toxic patients are limited to case reports and several small series. "-" We therefore report our experience with an additional 14 patients. We were particularly interested in patient tolerance of OAC and the effects of OAC on serum theophylline half-life, toxic symptoms, and outcome. Fourteen patients with serum theophylline levels greater than 30 (~g/ml and clinical manifestations of toxicity were studied. An investigator (CNS) was notified by the toxicology laboratory personnel of patients with theophylline levels greater than 30 pglml. Demographic data, details of theophylline medication and administration, factors possibly affecting dosage and drug clearance, and symptoms of theophylline toxicity were obtained from patients and from the hospital chart. A second serum theophylline level was drawn and the first dose of OAC administered at time zero. At least two additional serum theophylline levels were drawn on subsequent odd numbered hours, and additional doses of OAC were administered on even hours, approximately every two hours. The OAC was discontinued when the theo~hvlline level had decreased to less than . , 20 ~g l m l .
Symptoms of theophylline toxicity were reusessed at this time.
Approval of the pmtocol was obtained from the Committee on the Conduct of Human Research ofthe Virginia Commonwealth University.
Serum theophylline concentrations were measured using highpressure liquid chromatography." Activated charcoal was administered as a 30-g dose of Acta-Char mixed in 300 ml of tap water. The OAC was administered by mouth to all patients except Nos. 7 and 11 to 14 who received OAC per nasogastric tube. In some cases, chocolate flavoring was added to the OAC. Sorbitol, 50 to 70 ml of 70 percent solution, was administered following every other dose of OAC. When the initial dose of OAC was vomited, metoclopramide, 20 to 50 mg, was given intravenously prior to administration of further OAC doses. Intravenous fluid administration. electrolyte replacement, and other supportive measures were used as necessary. Initial management of the three intentional overdose patients included nasogastric tube placement and gastric lavage. obtained throughout the treatment period. Figure 1 illustrates serial theophylline concentrations for a typical case (patient 1) plotted in a logarithmic fashion against time.
Data Analysis
Patients were divided into group 1. who tolerated OAC therapy and group 2, who vomited all doses of'0.4C. Data arr expressed as mean standard deviation. Statistical analyses were carried out using linear regression. Student\ unpaired t-test, arid Fisher\ exact test as noted.
Clinical Featttres and Presentation
The initial serum theophylline concentration ranged from 31.9 to 93.7 pg/ml with a mean of 38.3 2 19.4 pglml ( Table 1) . The initial theophylline level was greater for group 2 (76.6 + 17.7 pFJmI) than for group 1 ( 3 8 . 2 2 6 . 2 pglml) using Student's unpaired t-test (p <o. 002).
Mean age was 52.32 20.5 years. There were eight . ,
. .
men and six women. Nine patients had a history of
The half-life of theophylline before therapy (tYd for cases 1 to 4. 7. and 9 was calctrlated from the initial serum theophylline concentrachronic bronchitis and/or emphysema, four had a tion (Ci) and the serum theophylline concentration obtained history of asthma, and two patients had no known 4 .6+3.7 hours later, just before beginning therap!; (Co). In five obstructive lung disease. Age, sex, and underlying cases (X,10. 11,13.14), the Co was greater than Ci, and in threecases lung disease were the same for groups 1 and 2, Nine (5, 6. 12) , the values were essentially the same, suggesting continued patients, including all group 2 patients, had ingested a absorption was occurring and making an accurate measurement of half-life before therapy unobtainable.
sustained-release theophylline preparation, four in-
The half-life during treatment (tY2t) was calculated fmm Co and a gested plain amino~hylline tablets, and one was replot of two to four additional serum theophylline concentrations ceiving intravenous aminophylline. A number of factors may have contributed to the development of theophylline toxicity (Table 1) . Ingestion of an excessive dose of theophylline due to patient error, physician error, or intentional overdosage was common. Factors which may have reduced theophylline clearance included congestive heart failure in four patients and liver disease in one patient. These factors remained unchanged during the treatment of toxicity except for improvement in congestive heart failure in patient 7. No patient was taking a medication known to reduce theophylline clearance. Three patients were cigarette smokers.
The three patients who had taken intentional overdoses had the three highest serum theophylline levels and were unable to tolerate OAC. Intentional overdose was significantly more frequent in group 2 (p = 0.01 by Fisher's exact test). There was no significant difference between groups 1 and 2 for any other cause of excessive ingestion or reduced clearance. Nausea (86 percent), agitation (79 percent), vomiting (71 percent), and sinus tachycardia (71 percent) were the most frequently encountered manifestations (Table  1) . Criteria for severe theophylline toxicity have been ~r o~o s e d as (1) heart rate greater than EOIper minute, (2) multifocal atrial tachycardia or frequent premature ventricular contractions, (3) hypotension, (4) seizures, or (5) coma.' Six of ten group 1 patients and all four group 2 patients met these criteria for severe toxicity. None of our patients experienced seizures.
Treatment and Course
Ten patients (group 1) successfully ingested from one to four doses of OAC (mean = 2.3 k 0.8 ( Table 2) ). Patient 10 vomited his second OAC dose after rapid ingestion. All manifestations of toxicity resolved with treatment except for frequent PVCs in one patient (No 6) and persistent but improved tremor in two patients (Nos 3 and 5). The mean half-life during treatment (tYzt) was 5.6 + 2.5 hours for patients successfully treated with OAC.
A recently proposed mathematical model of theophylline elimination during OAC administration suggests that OAC causes the largest percentage change in half-life (%At%) in those patients with the longest initial half-life, (t%b), where %At%= (tY2b -t%t) x 100 / tYzb.I3 Using data from the six patients in whom we were able to calculate t% before therapy (Nos 1 to 4, 7, and 9), we found a significant correlation between t%b and %At% ( r = ,912, pC0.02 by linear regression). This confirms the finding that those patients with the longest initial t% can expect the largest percent reduction in t4i.
A recent study comparing the effect ofdifferent OAC dosing regimens on the reduction in theophylline t%t in normal volunteers revealed that larger doses and more frequent administration result in slightly greater theophylline elimination. l5 Although our study was not designed to address this question, comparison of %At% and total OAC dosage for patients Nos 1 to 4, 7, and 9 revealed a trend consistent with these conclusions, although not statistically significant (r= .570, p = NS by linear regression). Each ofthe four group 2 patients vomited all doses of OAC administered. Charcoal hemoperfusion was performed in three patients (Nos 11, 12, and 13) because they had high serum levels, markedly prolonged pretreatment tYi' s, and continued to be symptomatic after repeatedly vomiting OAC. With charcoal hemoperfusion, the tYzt fell to 5 . 2 2 1.0 hours. All symptoms of toxicity resolved following charcoal hemoperfusion in patients 11 and 12. Symptoms of toxicity except hypotension improved with charcoal hemoperfusion in patient 13. However, she developed acute renal failure and sepsis, and died 13 days after admission.
All patients treated with charcoal hemoperfusion developed transient thrombocytopenia, to nadirs of 43,000, 77,000 and 95,000 cellslpl. A reduction in hemoglobin of about 5 gldl was noted in two patients and two developed mild hypocalcemia.
Patient 14 suffered a cardiac arrest and died prior to any effective therapy. A serum theophylline concentration obtained shortly before death was 32.6 pglml. In contrast to the tYzt' s observed with OAC therapy and charcoal hemoperfusion, the tYzt for patient 14, in whom no effective therapy was administered, was 20.4 hours.
Twelve of the 14 patients presented with manifestations of theophylline toxicity in the emergency department, one as an in-patient on a medical ward (No. 5), and one in an intensive care unit (No. 7). Seven patients were treated in an intensive care unit and four patients on a medical ward. Three patients (Nos. 4, 9, and 10) were treated in the emergency department and then discharged after resolution of all symptoms of toxicity and a decrease in the theophylline level to the nontoxic range.
DISCUSSION
Treatment of theophylline toxic patients has been largely limited to withdrawal of the offending agent, observation and supportive measures, and treatment of arrhythmias and bther adverse sequellae. Recently, attention has focused on orally administered activated charcoal and charcoal hemoperfusion to enhance the clearance of theophylline and speed up the resolution of toxic symptoms.
In our study, ten of the 14 patients with serum theophylline concentrations greater than 30 pg/ml and symptoms of toxicity ingested OAC without vomiti~le the dose(s). The result was a rapid reduction in the theophylline half-life during treatment (tMt) to 5.6 2 2 . 5 hours and amelioration of toxic symptoms.
This success is comparable to that ofother investigators in healthy and toxic ~u b j e r t s . ' -~~ A reduction in theophylline half-life of approximately 50 percent to 3.3 5 0.4 hoursB and 4 . 6 2 1.3 hours1" has been demonstrated in normal subjects. Comparable results have been described for four theophylline toxic patients with a mean tYzt of 8.0 k 3.9 hoursu and five patients with a mean t%t 0f4.9 t 0.8 hours13 using OAC dosing regimens similar to ours.
Orally administered activated charcoal reduces the theophylline concentration by two mechanisms. First, OAC enhances clearance of theophylline from the blood stream, reducing the half-life. During this "gastrointestinal dialysis," adsorption of theophylline from gastrointestinal fluids by OAC establishes a concentration gradient favorable to diffusion of theophylline from the circulation into the gastrointestinal lumen which allows further adsorption to the charc o a l . '~e c o n d l y , OAC binds ingested, unabsorbed theophylline in the stomach and gastrointestinal tract preventing further absorption.' Thus, OAC is particularly effective for patients who have ingested sustained-release preparations andlor having rising serum theophylline concentrations.
The use of sustained-release preparations in the treatment of obstructive lung disease has increased markedly in recent years. Sustained-release products are frequently only 50 percent absorbed at five hours after ingestion while approximately 90 percent of theophylline in anhydrous theophylline preparations (aminophylline) is absorbed within one hour of ingestion in normal subjects.'' We observed rising or stable theophylline levels (based upon two or more serum theophylline levels drawn 3.8 + 1.8 hours apart) prior to treatment in eight patients, seven of whom had ingested sustained-release preparations. The estimated time from the last dose of theophylline to the initial serum theophylline determination was less than five hours in five of these seven patients suggesting continued absorption was occurring.
Theophylline toxicity is typically managed in an inpatient setting where cardiac monitoring is available.
Of the 12 patients who presented in the emergency department with theophylline toxicity, three (Nos 4,9, and 10) were managed entirely in this area and discharged after resolution of toxic symptoms and a decrease of the theophylline level to the nontoxic range. The duration of time from the diagnosis of theophylline toxicity to discharge for these patients was 10.7, 8.3 , and 10.6 hours. The rapid clearance of theophylline induced by OAC in patients with moderately severe theophylline toxicity and no other active medical problems may avoid unnecessary hospitalization.
Nausea was present in 12 of 14 patients and a history of vomiting reported in ten of 14. Despite these complaints, the majority of patients successfillly ingested OAC without vomiting. The ten patients who tolerated OAC (group 1) had initial theophylline concentrations less than 50 pg/ml whereas those four patients who vomited the OAC (group 2) had theophylline concentrations greater than 50pglml both when initially sampled and at the time OAC was first administered. Ten theophylline toxic patients from three recent reports1'-'"ingested OAC without vomiting. The initial theophylline concentration was greater than 50 pg/ml in three cases; however, the level had fallen to 50 pg/ml or less when treatment with OAC was begun in two of these cases. Data were not presented in the third case'vo determine if the theophylline level had decreased from the peak level of 59 pg/ml by the time OAC was administered.
The OAC was administered via nasogastric tube in five patients including all four group 2 patients. It is possible that administration of OAC via a nasogastric tube promoted vomiting; however, vomiting was present prior to passage of the tube in all cases. Additionally, True et al* described three toxic patients who received OAC by nasogastric tube and did not vomit. Rate of administration of OAC by mouth or per nasogastric tube may be important as vomiting may follow rapid administration.l"Because of the risk of aspiration, airway protection must be insured in obtunded patients who have markedly elevated serum theophylline concentrations and are thus at risk for Treatment of Theophylline Toxicity (Sessler, Glauser, Cooper) aspiration of vomited OAC. '8 Charcoal hemoperfusion is effective in reducing the serum level of theophylline through enhanced clearan~e.'.~' Three of our patients who were unable to tolerate OAC were treated with charcoal hemoperfusion with a reduction in tYzt to 5.2k1.0 hours. Similar tMt's of4.7 and 3.9 hours have been reported for theophylline-toxic patients treated with charcoal hemoperh~i o n , '~~' although the mean tYzt for a series of six patients was only 1.3 + 0.5 hours.' Thrombocytopenia, anemia, and hypocalcemia were observed in our patients as has been described by other^.^"^^ In summary, oral activated charcoal is an effective and generally well-tolerated technique for speeding the resolution of toxicity and reducing the serum theophylline concentration in patients with serum theophylline levels in the range of 30 to 50 pglml. Activated charcoal is readily available and ingestion is rarely accompanied by adverse effects.= Charcoal hemoperfusion appears to be at least equally as effective as OAC for enhanced clearance of theophylline and resolution of toxic symptoms. Further absorption of ingested theophylline is not prevented by this technique; thus, the addition of OAC to hemoper-hsion may speed recovery, particularly when sustainedrelease preparations have been ingested. Since charcoal hemoperfusion is not universally available, requires appropriate equipment and skilled operators, is expensive, and may be complicated by potentially serious side effects, the use ofthis technique should be limited to those patients who are unable to tolerate OAC and/or have life-threatening complications of theophylline toxicity.
